.png)
Loading...
Email
Linkedin
Facebook
X
Copy Link
TranscriptAverage support for environmental proposals has declined from 35% in 2022 to 12% thus far in 2024—even as more proposals are going to a vote. Are investors bored with green issues—or is something else causing the decline?
Join Steve Odland and guest Merel Spierings, Senior Researcher, Governance & Sustainability Center to find out what environmental and social issues shareholders are focusing on this proxy season, how the Supreme Court's decision on race-based admissions is affecting companies’ diversity-related practices, and why board directors are receiving strong support.
For more on this topic from The Conference Board:
C-Suite Perspectives is a series hosted by our President & CEO, Steve Odland. This weekly conversation takes an objective, data-driven look at a range of business topics aimed at executives. Listeners will come away with what The Conference Board does best: Trusted Insights for What’s Ahead®.
C-Suite Perspectives provides unique insights for C-Suite executives on timely topics that matter most to businesses as selected by The Conference Board. If you would like to suggest a guest for the podcast series, please email csuite.perspectives@conference-board.org. Note: As a non-profit organization under 501(c)(3) of the IRS Code, The Conference Board cannot promote or offer marketing opportunities to for-profit entities.
C-Suite Perspectives / 04 Aug 2025
More C-Suite leaders view their boards as effective in 2025, but numerous challenges remain, including keeping up with AI.
C-Suite Perspectives / 29 Jul 2025
We break down the latest data from The Conference Board Consumer Confidence Index®, released today.
C-Suite Perspectives / 28 Jul 2025
Learn how Clorox invested in technological innovation so it could continue delivering superior consumer experiences.
C-Suite Perspectives / 21 Jul 2025
2025 is half over. What issues should human capital leaders focus on during the rest of the year?
C-Suite Perspectives / 14 Jul 2025
Learn why culture and constant innovation are essential to developing life-changing biopharma treatments.
C-Suite Perspectives / 07 Jul 2025
We've just passed the midway point of 2025 -- what are the top 10 priorities for chief marketing officers (CMOs) for the rest of the year?Â
